FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2337702988> ?p ?o ?g. }

• W2337702988 abstract "Background: The North American Research Committee on Multiple Sclerosis Registry (NARCOMS) captures self-reported disease modifying therapy (DMT) information and patient-reported outcomes from persons with MS. Previous reports show that those who remain on the same DMT report less disease worsening than those who switch.Objective: Assess characteristics of persons with MS who switch from an parenteral DMT [interferon beta (-1a IM, -1a SC, -1b), glatiramer acetate, natalizumab] to an oral DMT [dimethyl fumarate (DMF), fingolimod (FIN), teriflunomide (TF)].Methods: US residents who reported a switch from a parenteral DMT to an oral DMT in Spring or Fall survey in 2011-2013 were included in the analysis. Switching to DMF/TF was not captured until Fall 2012. We compared socio-demographic factors, Patient Determined Disease Steps (PDDS) as a measure of disability, and relapse activity as reported at the time of the switch and 6 months later. Results are reported as mean (SD), median (IQR) or [percnt], as applicable.Results: 595 registry participants indicated switching to FIN (n=278), DMF (n=238) or TF (n=79) from a parenteral DMT from 2011-2013. Switchers were 81.7[percnt] female, 51.6(9.8) years old, with mean disease duration of 14.6(8.4) years and 97.9[percnt] had health insurance. Median PDDS of switchers was 3(1, 5), with only 16.8[percnt] reporting PDDS worsening of at least 1 point as compared to 6 months before the switch. Relapse during the 6 months before the switch was reported by 26.1[percnt] and symptom worsening by 35.0[percnt] of the switchers, while 4.7[percnt] (23/486) reported a relapse in the prior 6 months.Conclusion: Follow-up on those taking the oral DMTs provides important information on switching behavior. Most participants that switched reported worsening in PDDS, symptom worsening, and/or switched following relapses. Patient-reported outcomes provide a practical way of describing disease activity and comparing switchers with those remaining on an established DMT. Disclosure: Dr. Salter has received personal compensation for activities with GlaxoSmithKline as a consultant. Dr. Cofield has received personal compensation for activities with Teva, Orthotech Biotech, the American Academy for Orthopedic Surgery, and MedImmune. Dr. Glenski has received personal compensation for activities with Teva Pharmaceuticals Industries Ltd. as an employee. Dr. Tyry has nothing to disclose. Dr. Cutter has received personal compensation for activities with Apotek, Ascendis Pharma, Biogen Idec, Cleveland Clinic, and GlaxoSmithKlein. Dr. Fox has received personal compensation for activities with Biogen Idec, GlaxoSmithKline, Inc., Novartis, Questcor, Teva, and Xenoport. Dr. Fox has received research support from Novartis. Dr. Marrie has received research support from the Canadian Institutes of Health Research, Multiple Sclerosis Society of Canada, National Multiple Sclerosis Society, Rx&D, Consortium of Multiple Sclerosis Centers, and Sanofi-Aventis Pharmaceuticals, Inc." @default.
• W2337702988 created "2016-06-24" @default.
• W2337702988 creator A5016172583 @default.
• W2337702988 creator A5025601552 @default.
• W2337702988 creator A5025979728 @default.
• W2337702988 creator A5029734617 @default.
• W2337702988 creator A5041022399 @default.
• W2337702988 creator A5057717799 @default.
• W2337702988 creator A5081587560 @default.
• W2337702988 date "2015-04-06" @default.
• W2337702988 modified "2023-09-28" @default.
• W2337702988 title "Characteristics of Switchers to Newer Therapies in the NARCOMS Registry (P3.282)" @default.
• W2337702988 hasPublicationYear "2015" @default.
• W2337702988 type Work @default.
• W2337702988 sameAs 2337702988 @default.
• W2337702988 citedByCount "0" @default.
• W2337702988 crossrefType "journal-article" @default.
• W2337702988 hasAuthorship W2337702988A5016172583 @default.
• W2337702988 hasAuthorship W2337702988A5025601552 @default.
• W2337702988 hasAuthorship W2337702988A5025979728 @default.
• W2337702988 hasAuthorship W2337702988A5029734617 @default.
• W2337702988 hasAuthorship W2337702988A5041022399 @default.
• W2337702988 hasAuthorship W2337702988A5057717799 @default.
• W2337702988 hasAuthorship W2337702988A5081587560 @default.
• W2337702988 hasConcept C118552586 @default.
• W2337702988 hasConcept C126322002 @default.
• W2337702988 hasConcept C187212893 @default.
• W2337702988 hasConcept C2776036978 @default.
• W2337702988 hasConcept C2776819417 @default.
• W2337702988 hasConcept C2777703276 @default.
• W2337702988 hasConcept C2778577042 @default.
• W2337702988 hasConcept C2779134260 @default.
• W2337702988 hasConcept C2780640218 @default.
• W2337702988 hasConcept C2781004633 @default.
• W2337702988 hasConcept C2910384678 @default.
• W2337702988 hasConcept C512399662 @default.
• W2337702988 hasConcept C71924100 @default.
• W2337702988 hasConceptScore W2337702988C118552586 @default.
• W2337702988 hasConceptScore W2337702988C126322002 @default.
• W2337702988 hasConceptScore W2337702988C187212893 @default.
• W2337702988 hasConceptScore W2337702988C2776036978 @default.
• W2337702988 hasConceptScore W2337702988C2776819417 @default.
• W2337702988 hasConceptScore W2337702988C2777703276 @default.
• W2337702988 hasConceptScore W2337702988C2778577042 @default.
• W2337702988 hasConceptScore W2337702988C2779134260 @default.
• W2337702988 hasConceptScore W2337702988C2780640218 @default.
• W2337702988 hasConceptScore W2337702988C2781004633 @default.
• W2337702988 hasConceptScore W2337702988C2910384678 @default.
• W2337702988 hasConceptScore W2337702988C512399662 @default.
• W2337702988 hasConceptScore W2337702988C71924100 @default.
• W2337702988 hasLocation W23377029881 @default.
• W2337702988 hasOpenAccess W2337702988 @default.
• W2337702988 hasPrimaryLocation W23377029881 @default.
• W2337702988 hasRelatedWork W1513376344 @default.
• W2337702988 hasRelatedWork W1547439455 @default.
• W2337702988 hasRelatedWork W2297458587 @default.
• W2337702988 hasRelatedWork W2408797304 @default.
• W2337702988 hasRelatedWork W2530449530 @default.
• W2337702988 hasRelatedWork W2546905376 @default.
• W2337702988 hasRelatedWork W2562735552 @default.
• W2337702988 hasRelatedWork W2574287154 @default.
• W2337702988 hasRelatedWork W2594317413 @default.
• W2337702988 hasRelatedWork W2780471718 @default.
• W2337702988 hasRelatedWork W2904039091 @default.
• W2337702988 hasRelatedWork W2951536881 @default.
• W2337702988 hasRelatedWork W3173117651 @default.
• W2337702988 hasRelatedWork W3176514303 @default.
• W2337702988 hasRelatedWork W3212871123 @default.
• W2337702988 hasRelatedWork W1847061406 @default.
• W2337702988 hasRelatedWork W1882539886 @default.
• W2337702988 hasRelatedWork W2155100555 @default.
• W2337702988 hasRelatedWork W2171569640 @default.
• W2337702988 hasRelatedWork W2545472930 @default.
• W2337702988 hasVolume "84" @default.
• W2337702988 isParatext "false" @default.
• W2337702988 isRetracted "false" @default.
• W2337702988 magId "2337702988" @default.
• W2337702988 workType "article" @default.